Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors

238Citations
Citations of this article
312Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and Purpose: We sought to understand why (−)-cannabidiol (CBD) and (−)-cannabidiol-dimethylheptyl (CBD-DMH) exhibit distinct pharmacology, despite near identical structures. Experimental Approach: HEK293A cells expressing either human type 1 cannabinoid (CB1) receptors or CB2 receptors were treated with CBD or CBD-DMH with or without the CB1 and CB2 receptor agonist CP55,940, CB1 receptor allosteric modulator Org27569 or CB2 receptor inverse agonist SR144528. Ligand binding, cAMP levels and βarrestin1 recruitment were measured. CBD and CBD-DMH binding was simulated with models of human CB1 or CB2 receptors, based on the recently published crystal structures of agonist-bound (5XRA) or antagonist-bound (5TGZ) human CB1 receptors. Key Results: At CB1 receptors, CBD was a negative allosteric modulator (NAM), and CBD-DMH was a mixed agonist/positive allosteric modulator. CBD and Org27569 shared multiple interacting residues in the antagonist-bound model of CB1 receptors (5TGZ) but shared a binding site with CP55,940 in the agonist-bound model of CB1 receptors (5XRA). The binding site for CBD-DMH in the CB1 receptor models overlapped with CP55,940 and Org27569. At CB2 receptors, CBD was a partial agonist, and CBD-DMH was a positive allosteric modulator of cAMP modulation but a NAM of βarrestin1 recruitment. CBD, CP55,940 and SR144528 shared a binding site in the CB2 receptor models that was separate from CBD-DMH. Conclusion and Implications: The pharmacological activity of CBD and CBD-DMH in HEK293A cells and their modelled binding sites at CB1 and CB2 receptors may explain their in vivo effects and illuminates the difficulties associated with the development of allosteric modulators for CB1 and CB2 receptors. Linked Articles: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

References Powered by Scopus

Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

18946Citations
N/AReaders
Get full text

The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling

6274Citations
N/AReaders
Get full text

Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors

2774Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antioxidative and anti-inflammatory properties of cannabidiol

531Citations
N/AReaders
Get full text

Cannabidiol adverse effects and toxicity

304Citations
N/AReaders
Get full text

Immune Responses Regulated by Cannabidiol

203Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British Journal of Pharmacology, 176(10), 1455–1469. https://doi.org/10.1111/bph.14440

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘250255075100

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 92

60%

Researcher 39

25%

Professor / Associate Prof. 21

14%

Lecturer / Post doc 2

1%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 43

36%

Biochemistry, Genetics and Molecular Bi... 31

26%

Chemistry 24

20%

Neuroscience 23

19%

Save time finding and organizing research with Mendeley

Sign up for free
0